Phase II study of L-BLP25 (Stimuvax) in combination with androgen deprivation therapy and radiation therapy in patients with high-risk PCa. L-BLP25 vaccination is thought to work via killing of MUC-1 overexpressing cancer cells. Here, MUC1 is linked to cancer.